اعلان هااااااااااااااام


Translate

How A Creative Biotech VC Exit Looks in 2013

Wednesday, February 27, 2013

WN.com - Health News
Latest headlines from WN Network
How A Creative Biotech VC Exit Looks in 2013
Feb 27th 2013, 13:12

The lack of a strong IPO market makes life tougher for biotech venture capitalists. Boston's Third Rock Ventures has done some creative deals to try to get a return. Details on one interesting one were revealed in the purchase of a company called Lotus Tissue Repatin by Shire. Details were revealed in a recent 10-K: Acquisition of Lotus Tissue Repair, Inc ("Lotus") On February 12, 2013 Shire completed the acquisition...
You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 Responses to How A Creative Biotech VC Exit Looks in 2013

Post a Comment